/

ࡱ>  QbdfhjP  !"#$%&'()*+,-./0123456789:;?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`acdefghijklmnopqrstuvwxyz{|}~Root Entry F`,]@^R-Workbookه _VBA_PROJECT_CUR"&^@^VBA ^@^ \ptask Ba=-B0=830=T$@"1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1̳Arial1 ̳Arial1̳Arial1̳Arial1@ ̳Arial1 ̳Arial1̳Arial/#,##0"@.";\-#,##0"@."9#,##0"@.";[Red]\-#,##0"@.";#,##0.00"@.";\-#,##0.00"@."E #,##0.00"@.";[Red]\-#,##0.00"@."k*3_-* #,##0"@."_-;\-* #,##0"@."_-;_-* "-""@."_-;_-@_-k)3_-* #,##0_@_._-;\-* #,##0_@_._-;_-* "-"_@_._-;_-@_-{,;_-* #,##0.00"@."_-;\-* #,##0.00"@."_-;_-* "-"??"@."_-;_-@_-{+;_-* #,##0.00_@_._-;\-* #,##0.00_@_._-;_-* "-"??_@_._-;_-@_- 0.000[$$-409]#,##0.000 #,##0.00"@." #,##0.000;[$-FC19]d\ mmmm\ yyyy\ "3."A[$-FC19]dd\ mmmm\ yyyy\ \3\.;@! ! ! ! ! ! ! ! ! ! ! ! ! ! !     h<  |< "x< x<  h< x< 0  (   h< x;    $  |<  d<  #|< |;  l; "|< "x< 8"@ @ <"@ @  (@ @  ,@ @ (8@ @  8@ @  j(9jJ219م>\`@09A data;   ; T oz zbzP2{It,l ynyP2{It,l PNG IHDRI"!sRGB pHYs+yuIDATx^]`^@]B 򪴅+Zk@H'nwg"K1-̝sϽs\*e!p0` 0`ߋ8 0` 0`` 0` H 0`YLGZC?À 0`G0`&j b^bŀ 0`b]̤tNI+)dJ{E`^> '/00`` 0Ha(h ZB 0`h t΀2` 0`~(5 l5 M_l6j&ϢlkJ/W).qr V"pq tZFL?9U$ƾ}%nDbel2- ª`tqI5m\ZАPV[UQP[^Y^+("BV DKSS}(O?w+ZE]dx բԊښJ0Z@'s4fsMM9Ns1 rBıCbL[Ĵ8O/gS J 6Wݛv(AHgAP|V:!԰G32.$WWW7(#H/k7sO9)n[BY;̱qr48QUS\^Q]S-fTV\B |,@k>vr Cۑ}oOdP) HdӧuRɬC)g-ޕQfu;s(Uo+Z,(lȮYO7;i 4Jwf]PӧQ5yꋩ O cO~#!xѨ⋲z36C(P bp@`54N؞A'>U xv +Tu+mM!,DgC [~hZ%m^aV=k/&Jianyf=\ 4i+FW4w2]sh޼jaBMf>)e΂ :06UŧdH9.fapw PDٵ\!*Bmz6#D6R8O2T*H8?ZHNKaEݙεlh@>ugrK4ljcduRinEcrX+;"]&ߐ1voEԡa*ʰc0=Iu2xkn\vwtq3h$>sho7s[.=uϕ32^?ypŴ[سWŜwO3V,y}]ܸpVl^ˇM=̾-6&-zԮ?ߚxcIk٦LL`S~1#RHh]*@ɥ b^ӥg2B(2hd%c=9o1g8K^;D t06F{sbwvKK2=s]M㦽2`[OΩ#C,LTVq9GO];c/sai~/3c .I` gD ^=,E"H`ViqDrm`J*+ݘ,̴R f [K'(.Y,;+O01 ƐH o{'[JOy:b(DN79IWOZV?f200&9Rȟm]lj䄞S0 `FԾ[wܩ̔:qV8M鳽lh<2['a?zRq=$.zat)4Pv(mm6Mq^ (]~ē7BȀ:18WS=[%4 k^;~80$)1 0nՅlʰR&ܩעHpDukm.njEȨj"*v9BJ.}c ]4Ygcwnbq>?3%H`<%TڪsٙeeŏD.ժe_":z OM)-LwhX7sa}?Ct FRqgcyM+i }a KTxZXalg@'aKw^8hg26ZdLxs`j6p`1LG2fav8bj7f]e{GZ{_^][`p+RߠCL, VPW7R +Eݾu8=6:+zZZFPjeǁcppF0;?ImMd% 1,X/Jv*;(8Ņ~ta.1j.l<|5#~CVwF\h @-.GC-I|jKs64TS\)ˠ %Lj-6L[hjI D^!;Wx CmD $QhV4a1:bĚ@Od27~}'ö{1/juq ~ Z gF*ogLABNZ ܷJ*kgΒ~r7S6{-"Ywޚ_SPI>c[V|nU!`"`ץE 8)5b DB'76ºHic`upZa-%CӪg\_R_=efLwʀ>^s~/Lf؛rc?\\Scp{'XOΨ,ۈay./|_π'RT?omz_ޏ\ײv}{ֻ~a_?=sgΐoq~h% #3Qjp@AdZ8TWlucau?s;mjW&!Lƙ}~7\R0έ"B$th)^/sޙ'櫓Mz:8C@Ufc3ӊ"C|^ Tn1FvІj9}gU0DQ5"pdqi kbϽuxfK)> CI}]JYrh7w?~R^_i {ЕlbT(t#JK-)o.DA(AE15{IcEF3RduÞ3.:"cbAk@-Xbpc000z-ڎ- pS*!KxDH El@;?9A*uLr# #rfeD8:cڝIq{=E=# XٚQo~&;H-[#Ra&0J+C흘,//z5CfsqtKآNzr{>}QkoJd&B4&ܖ,rȚc2$8A4!bF(VBj~x;vZ|lዯ Zn#=1.7K ڱ5ƹV4"sTxZc㷇>rⱙsSfe =mޔPŐw~ج ESk59b:ClޞTh5}k4 r|gir..ܖ1~D]]/*Xߕ) (S4<Q T;{0&.kE; "cXe5\Xc&1̹Xf/ _Fg!f4۹W}U.r VnU1.Z)D!%NUO;G#ڛRĠە <fN.eLEU='SB?o3{7\˻ )LK$:6ٛFʤDs+3z~=vIߙt#O}7g`H+Q~j1Gm"wpYCcbUKf/Oz*;[N*-M)j|:ӷ/zai `T.L60KcE=\)"1F`f'3qM 3ᬝ;'ZdL 6BAL[ ϼ ,F‚ZH0vN na/nb&#!\$'p\ Bo"1c 4rX&K,c0b r9&| @fB/P-M1M\VVBSI4`s;u9Κ9U5U #ćyo Ory_'NEkoց+v/q'Lx%"] [YqDImwv| RIH6Okڜ;Ͼ5sGL  0i}eX,wDZ%,|{R|ֵ(jډ.oO-Kh^l={#E֣=c/ kA^[ZiqlK+ ;fQ> Sm7_}OieVQ*,.Nнnef"Y oݑtb[Eo`0Pϡ_nu[N;1B.V ^3uLRTP/asN#KXƄ؃i\@W؍SV.>xme9|o~qW6~0&Kx ܸ+WO'zy=g Q 8t21Ƕdhը]Ιӓ$u5B.wOJ‘+[nEIZY+Tlj-p*J(9v;bղX)Jb! /3\ 75r CX~6jڵD1$SK<\c'Xw7&@*l*jd vAMŚ+!E۬|w;}Ldjil3Kj]z:&d=xӱ+^;'7̽-mTy$wҵ7p_'B8ҪWE^z x^~ D` d|[&.M`}svrK&$9nc3CK)O'}9PVu1pc >mӌLoysܕ"՚y_rhoO޼GYubi18drXYUUq =|6z>ˊn_;Fk6zҴ^BV߽NDZ`-$2Y\$1jmk'4,f_VJ}\<7T}kH獱A@~NfwKƟVMdj>-[c`IJq mՅ ~} u#n"&_1 C?T <ϳ[~ul"4F(7in^yi'̾44m@xU6(ʐt*Fț { RLWlANE%DR~5b q_E!VKpyo|`NI GhP${P%\.Q&|_:D`oPHn=z_8@LQUR-EG?2 n~bLǩbT_0V@T= v+.4iCjk"&,Ó)oؕTY*KP"J(j+Ct7"nok_FTpP-a+OGgf԰y|K\Iq* eHJ(oC3 H:aZ>xYc9z+`‰u {v1WVFREg'/Lw[oJ8 4T'"ۨ`ोEWk1^"Fc96,nuZ4$٦Y)t9pG?T) c  Yƅ'^71~'S!f-"Òo#Z-5b,'SrQH _(,-Z3k>)cȯXAoAκIn^&I8HQ3v5/kom}|jUk~v}2A4jjZF,a;&d ~ݽ1 ;QI7|b/0A*|0A)Owlѳ86v%/lXwu\nD.^ #pw$^#tOv?O!UFff)oԶ(c+GTvtf:}VH۷ٜyWn6?Ic[v\>4{W-|DFI=KOyv} / ?L;3$\(zۉe (nMʺ"v2yY}]ԲJe~µLLz{i4v+FK_܉Yͻ00hn#~8jk$`_a4SQG׭:ﴖ~t#bVWʽݚ^dJCy# 4['/F'Q>NDƝ4ҶuYA,."Ȼ>6kx0w a!UJïmbW Fm})7R](w.,]t/2nFBK8X!T/*q=H%&]辁AXID,*᫾N#EwF륒gOw[= ,RFucl~G SDLnR9/jdڿt li4HL^ltP 8o^GBjo2'm[wX `!.nB\e}%Դą@+y2wYr1PE4sCAq;67ju}a6~(wa'n\͹"h:Я-ҼZp'yZ@urW8sQ-=EIx/ٱq KdXU YQ fu}L?졈xW|㉾pXw*j鶄~ޞ:D `X @C!$BjA }PhIHEʕ[`+gi48x~ԗ=zpvfmV;Wł UQ6yY鰐X\ޠPX+HYݍߩVe[ e~وNjt6Zh05#=ILYtL}I-lK=p0Bi}M+l_+9\QU۵Vۻ؞7"ԭtԖ߯Bt׷,(5|׻RoHL۹NNOڸjo-wmԆy,skIܵakMxpﻫ_ٳy(iS&QlӇ?}o-Aʅn$V@uHb hZV6> gޢ[h܋E${lm뮔?=w4vD_W+Kl[gиʭb_4Jopܴ>SݜT2=w=x,BYb@:=4|{E+}f#[YS|VTSj]E|9CslԒjY GeE9;yi?6 ]8&fgUTI!lϦ*obڋh#<҆WUno{(_b.pO/%-+ٝ@u`rP3$<ݤ^In^m|lfboJܔ,7Rffӷ XxtCmcY|#I[Fc6WԈ1J4.tUplExv(DhRI͢Kl즎R{\PfۘFa]:!nL"jHz3n>蹥=6iPG$-YƙVCj!Ůua *cְ5q\}4b^:*19-OY[4;Ѻ^ r$z4)͑YieyFboE;^٘O/= _]<h ~.Ix5u.O%S|a}zAPqŨh5NۃG14C=PAh岚OLF\U!KLda%IQj,2X`v(&=#Ϫx^flG3 ?sM-}&=Gyc3% 4ӧ'|Q7 2?8} Qm_+U(2Լ S $KSYžb-2 n_c/Ar֙Јl#e"gS3lDEn!~]d2 I}T%)wʝͭE zHhVّ}QrSQWZhä]YWt4:pC&qdgU__j4nz}lr[Ly{n}t؆Xңa0WV||:'g]&-P"PNIu@`Il5x5HHg) "5bZl؉BQ'؝NÌA+xdsX\.QY׎TVftFk]ʽ;ӷF"~A|n?zxWV.4 7ü|d=J ~wޱb'2SSH;hQaE%)k'm[{=ΏgPADzO~A/>1h.j@1VH\œ YZ|=E&oJf?7ܸ6浒zWd܉qPrܦջcf7bD9WAG7d- K fn#޽=x{ ugA46J疸+W sdݺmm~[QQM JRn[{=-h=d.^Ze\|;Ӌ}J.+@"!%HB4eZҒ2褛;⮮~q9ˤ҂{F(W]ȹV^8ڞaJfn@#)7.54=#`6>[oEroWUA;j8W߸KgвWP'QLKy7% %^qtm6p#^/;'p݅6.X]S?VTrgڻZ-/li{֍uqPgZZ8zêmθ[7brL|()4{%{#J|:M".gLȉuuIj"l"^O2`H}8&hb`P3R sSH}kݢJb/ [ܪH0Ie%0-i(z׭Gttnd-Xfg)栒?k19Wc]<9I w)!N[9S~D4yAgׁLy]ʈj_ J*{D>AWx|s{+#AoH e_7c{^-"mLO|4/t0TpP,vY@Di%gٳfy6(&䍿yC\^s>zu@Y<0WNWZZ@AlT9L9mi]+So0 g낂'Y)Dgb,(N1`ɝr_x:+l|c{o8c3жKV"Nݜ?㻢2)%a.TCGIҧ/ ݨck~s9wuC=|{H@'X+s &ӄc"vX@VS\N6?D^s!'K`bcczA&a4;t|q7OOkeRg&/fCnP"s'{q?KxC,/0_@(~QSɹQtN%$X|بx(J0?ʤ1x%R%tu0TQRGEY|T$Z0 )ݴFtgfm$0G`)X!݂ۛbT_;?Z߁V -j7=wW=\++k*}մR_HZkJ!l! YLvff~~~5ܢTI;qlvKv ͡z~"w_=K`f cKkEB7+H `$qƦ4Jd08DV=LIz.fLtE4u4Mmآ!C[XKKYw\@'OH2d]L@*KoXJ ./Es1@ت4grYCݽ{wv|yDvD"0mt"U*bh1׷{+"AE\."ZTBOZnC^AgQ Zwe #.Վܸr\H2$Z`gcEaeIp@o04ڊ#)(;SP7qQ~9T4J1]H4PJNwAbTFBjĺYR(x|DTUK4dDy0hk,=+%o#.70p9-YT|$ IHt|rpbG.c0II .ON׭bbx%`/ i֢%Av(rp,ji%y7 sF&::HVU fPi$[6 gװ:# j5j$tkyw"#GK5{2=1d`inyn;ߺes i,*!Hz^X]>gI(*; K;Pd0 c0u`:M+8x b8l&KP@b* {RJ;qo iKF)qeTUKnWTIR'5vҒ5j![1Ap"R࡚t}釒aH!0D>p"`X͉cvހΤ&`H9' @4 (gJ.  &h qvk MDr!?l6EHUT y} '`T!ӃRT 'gGm7NLaʍ@ *X,V-~EiByeRB;fkl),D&69a~>=W~} \6uZ8Y7_:D';Fr#ٙ߾}(ۛGXE o)WrFP^xR(&8ļia(Ic4r DyYV\RˉK# jD +S7R6bמk+_1NJ,wGGܻA?ӧ%^n^QN]QhF z >:oh mS^*JQwBPeWGe$[TIW]9};z 'QjU-˹|4WF.h0*ɩBۅyu埡Ş(+AET9F.Ilw1^nb' I!A͚Fx1ze)A1R gb:'W Plk˗l0[sT2BވڏvShrwk1>$Ãlߖ Cq,$;f$ ]=8OݣoSg>h韀ae1:9Z4/[m9FEFnfUT n"l졞/509=7h$(S2;^t}W_kVJIł~-T(E=+K*Q*" U;]T#;xg l7B#&kcӉ>&āбd-B9L9\AήzXXP{;{藨6/gB¬Gxpc !XRB[)s^{ Y줪B;(j>C=ɇT$<†hF vtlQr@aBQۜ}s+tQlfzπ v= țH%^4EtV5æ&.m+VY[@L]~I <#MNjI=%N=*6Ae##s1VRdZ(W%Ⱥ}L0t) kMGCO䠋z,4`_;nC]FŰh( $EI#k|E_I'(xZ_y/?GWdyR(LGoҺqNXjy DP4:&UpiM?$ƥibEBnhkTO' l { Zz+_9cglqD O)uA=ٴ([pf&KP4qL[F H|$.FD4$#֐2Vcʘ+y"a{ | $J5cE]߮W8y Ht ķE4bJyCdLM#/J *yS b)JXMra^' eGYޤ_lJ>WOZhdBӀ)!Dʣ 1@.c%xPxCX_3vEv 9? 9zo58ok{Fq}? i!kԶ&fqϽ2je,.ߑ> cտ0!I%(z 0NFb% )Cy2l@ikש[ٌM05bB$ŷY27S>d6+yڲWcyZ4&{P'T a b Cui 1Cy<pYA8S%whj" Qm0iNSN˽MRB\nUYf2= 1D p(+o]QRݺf*9ڝFCTR%2iWo$ŀ߮,i+ۊL:;$\E{"akz+vo•Z%)b+bMc0Ha>0Å$ue/`$vhtb ?iH:XFp#pK|t+x=lQz`EEki]UI-hf-;b.hdzI7$eLwdr~z#Εqnq`kNqXΝo,-STxhYx?T]oG-9|V N$ǣdҷ3LBk})b`T6mʒJ5/%Ξf-jG/GNYsJUCQ/+rqײ2SKec8nL@hWOҐ~9 gRpX6a@5vo e N__ 4b>MQa}ﭠ0G{R eDEf@ s'D Ձ*VB;lpҿ6v-wHL"Ճpv02Ҫ4"lw\vGG}l4z; 8z1_Ò)|6sP;E|{ȸ9F09M{ccR9Ͽ-]㼾QRժ%1-d_'<;3{^Ejdه=uhʇ=ЭhV\Wtgnlrwb5XR4^0|^M9j.Y'o5!j7i+G5ݹӯ<n8ԡ;'pTVFMC==Se G̦,R+ U|<*9&6QMFIR*$d8 0`k蜑-lP?wKj:{x=u 5r܃{>vfIL !Py_l$ߠa=̭yr娉(|N8+b=㨼1;n?|!=z,_pVOb*Gm&aF ƖP@QA#F&6UO:RnQ_|k[hZy ۂ=T-ާa~*9~jX߱^!;F&No6xє, bXh(V 9k"U7.K+#P:K(}mVm]x#0ɀQ>o/bPyR)6d 1Jv=|.ӫ1c*ُqrw]vDY=i&2 "Ui%>OG^"4GBs3YhPľNhoG5C4Ii](IGI-֋z;:ㅺwW`b -pK xI(파L8o_Se,ĶXh>xؾѮ8tn@wy9rnWWu`x\6+0*Sthb98vl3XPMe(k_/ݛ"~{jJ`*g6HnLfވ/D?Q{2mԙE/#]t6E/ōMT&+R#zYYI7*4Yl73KVrs3?c"cw]3ғѡ-==0wzpxԢLKG`{XZ7ܧ&\gD*Iu Ix֠O( yc4845:#PDWiH _JA4l舅lX5j(N|å ?3`ƒU>A'z5A2q.> =qYhtw0y\જ틧yH)`?NE$Qex^~@We=õM[!F>enaݎ#_YSmB+Lt"}EpJVݼ*.#!ۑ=hH99 =z-ߨDj3ч?8dJ@ivEETh}&gmB-_`dt03nuYpJe% /@L [P_P j`KLfgw腔E\PN /Suze2\M?`ŕ˥95 7c*kLDcO{lݩ(025>}88_5R'"7|s4W(dx:aN,ǩҰr>q14fC ʬ(;|#mήyGKi奅u`ֶLcr?6~aOx L^nbh3^}o‘.R {x{&F`a =w x'2ʮLŗs_>+Ev{01E_E-g넙=<%2Pb,<rUȲ+-l(GT\ofaIM1 U9CX̔#;[X}`ge O)J Qj+9“j2Iz JՇrUrLͽa*?^=) nC'n,|ϋϓCd{ˈ*EU%Ec=5G. N3 8=4.C?'! &.%  A B25@4.=0:>=5G. N5 8=4.C?!! &.%  N9 8@@830F.(320<;)!" - 6% D; 500 !10!" 0<? 2<3/<; 1<; N5!"  B01 5<3 N28!"  B01 10B @I.5AA8O, 74>@>2.8>B5E=>;>388)!" 2 35;L 4/;8F0 A >B>-MD.2;LB.2@>B.4/@>AB0 2>;>A 5@>B.?/@I.2/3;07 2<; N10#!"  A25G8 203.100<3 N5 Vetrose!(, Vetrose Inc!" $# -5 D; 500<; !10!""$"  D; 25;LH0, Phytopharm Klenka!" 0M@>7>;L 30<; IVAX!" @-@ D; 100<; IVAX(!"! / 684:.M<C;LA8O 200@8070!"! / :@5< 150@8070"!"! / H0<?C=L 200@8070 !""#!!-$" A8@>? 100<; IVAX!""#!! :0?;8 10<; IVAX!""#!! :0?;8 50<;!""#!! B01 N20 IVAX+!" !! .! A?@59 207 Reckitt/!&!" !! .! B01 4/@0AA N16 Reckitt !" !! B01 4/@0AA N24 Reckitt-!" !! B01 4/@0AA +" + N16 Reckitt '!" !! B01 4/@0AA + N8 Reck'!" !! B01 4/@0AA + N24 Reck(!" !! B01 4/@0AA "+-. N24Reck(!" !! B01 4/@0AA A ".! N24 Reckitt#!" "& !#,$" 13 8>E8@>H>: 23 $$ !" "& ?>@>H>: 23 54@0-$0@AA8O, 54@0-$0@< (!" "& @0AB2.;8=8<5=B 5% 303 86D0@<!!" "&/ <07L 10% 253 "25@L !" $ B01 8,75<3 N16 Reckitt !" / , .! D/?0: 23 N20!" / , D/?0: 23 N20!" !", .! D; 50<;!" !", D; 50<;!" $"  0,025% 1<; N10!" $"  0,025% 1<; N10#:@08=0, 0;8GD0@< !" #"# :0?A 250B5:A >AA8O, !>B5:A/Pierre Fabre!" #"# :0?A 500B5:A!" #, " B01 N50$!"#  B01 25<3 N50 Gedeon Richter!#! :0?A 250<3 N1202!#,! ?0AB0 1% 40D8;0:B8G5A:0O <0;L30<0 #:@08=0, <0;L30<0 N:A (!#,$"! B01 500<3 N10 $-5:A@54&!#,$&-Na BN1-:0? 20% 1<; N2 5;<54%!#,$ "- <07L 253 BC10 86D0@<!# :0?A 250<3 N6!# B01 125<3 N6!# B01 500 N30B0;8O, Roche!#  H8?.B01 N10 Bayer !# ! 400=- #! >AA8O, 545>=- #!/Hikma!# !" 25<3 B01 N20!# +   :0?A 200@B5 :@5< 4/B5;0 75 N100 " B01 ?/> 500<3 N5 Aventis5@<0=8O, Aventis Pharma!" 0<? 1<3/<; 2<; N5 Nycomed2AB@8O, Nycomed/Novartis",  40307",& 652.B01 500<3 N20" 407@0G=0O =0 ?@8A>A:5 8+ 17301"  A @CG:>9 5+ 17302$" '-"  A ;>65G:>9 173103" ' =5A:>;L7.A :@KH:>9, 28;:>9 8 ;>6:>9 17316"" :0?A 300<3 N100"" B01 600 N20 Sopharma" B01 ?/> N100 Sopharma " B01 ?/> N10 Dupnitza"" B01 N40$"- @5B0@4 B01 200<3 N50 $0@AA8O, $0@<0?M: $"- @5B0@4 B01 300<3 N40 $0@<0?M:" " B01 N30" $! :0?A N30" $! :0?A N60" $.   @>H>: N100=040, Patheon Whitby" $. -!"  ?>@>H>: N10" $. -!" " B01 ?/> N10"C@F8O, Novartis Urunleri"  :@5< 1% 153" $ :@5< 1% 103" $ B01 250<3 N14"  :@5< 4/=0@.?@89 "#B>G:0" 19004 " "  4/20==>9 19105 "09;0=4" "  4/2>4K "@01" 19106$" "  M;5:B@.9 " 161(259F0@8O, Microlife AG$" "  M;5:B@.<548F8=A:89 " 1622$" "  M;5:B@.<548F8=A:89 " 181$" "  M;5:B@.=8O, Bayer AG"!" =0 15@5<.5 #"8B09, Runbio Biotech Co Ltd."!" =0 15@5<.EVA!(, Milton Inc"!" =0 15@5<.EVA Miltom !(, Miltom Inc"!" =0 15@5<.FRAUTEST5@<0=8O, Human GmbH"!" =0 15@5<.FRAUTEST N2("!" =0 15@5;?0G:.%"!" =0 15@5<.FRAUTEST 2 :0AA+?8?5B:0 "!" =0 15@5;>A:05@<0=8O, AEiom GmbH'"!" =0 15@5<. "!" %' (<8=8AB@8?)0=040, Internationa2C;OF8N FRAUTEST N5""  B01 N10!;>20:8O, Notex L.L.C."" & /% 0,1 N20 5;<54("" &/ <07L 3% BC10 153 86D0@<"""#  0,15 B01 N30 $-5:A@54AB20#"--! 3;.:0?;8 0,25% 10<; N1""--! 3;.:0?;8 0,5% 10 500 500<3 N4 Polpharma!""& 600" 0<? 24<; N5 Baxter5@ 600 5D0@3>@A:("/ !",/ D/?0: 1,53 N20 $8B>D0@""  BP A- 50 ?>;C02B>;C02B.4803.0@8B.?C;LA0(""  BP AG1-30 @B.8B09, Microlife AG"   10 B01 ?/> 10 20 40<3 N30" ! 100B :0H;O A8@>?=48O, Plethico Pharmaceutical" ! B01 N16 <54" ! "+ #!#" #, ! 0<? 2,2<; N5" #, ! 0<? 2,2<; N100" #, ! :0?;8 30<;" #, ! <07L 503" " 0<? 5 100 400 N21" -  21+7 B01 ?/> N28E3" -  B01 ?/> N21" -  B01 ?/> N21E3" # -"# N50" !" B01 ?/> 250 N40 !>B5:A >AA8O, !>B5:A/Pliva" !, D; 200E8<8:" $" 0<? 0,2% 1 5@>2L5" % 203.B01 500<3 N10" % B01 250<3 N20" '" -  0,43 :0?A N40" ! 35;L 2% 403 Troyan!" ! :0?A 300<3 N50 Troyan'" ! #"   35;L 2% 403 Sopharma!" ! #" ' :0?A 300<3 N30" !! 35;L 303 BC10"  !! 50<3 B01 N302AB@8O, Lannacher"  !! 100<3 B01 N30)"  3;.:0?;8 D;-:0?. 0,5% 10<; Rom C<K=8O, Rompharm C.O."" #!(%  "!)B01 50A;5@>4>2.N2 @.S (156) 0104&" #!. 4>@>4>2K5 N4 @.L (156) 0111'" #!. 4>@>4>2K5 N5 @.XL (156) 0111%" #!. 4>@>4>2K5 N1 @.XS (156) 0113%" #!. 4>@>4>2K5 N1 @.XS (15;) 0113$" #!. 4>@>4>2K5 N2 @.S (156) 0113$" #!. 4>@>4>2K5 N3 @.M (156) 0113$" #!. 4>@>4>2K5 N4 @.L (156) 0113%" #!. 4>@>4>2K5 N5 @.XL (156) 0113&" #!. 4>@>4>2K5 N6 @.XXL (156) 0113'" #!. " 4>@>4.A 45:.M;.N3 (15;) 0500'" #!. " 4>@>4.A 45:.M;.N4 (15;) 0500%" #!.  4>@>4>2K5 N2 @.S (15;) 9902%" #!.  4>@>4>2K5 N3 @.M (15;) 9902&" #!.  4>@>4>2K5 N5 @.XL (15;) 9902$" #!. " ?>A;5@>4>2K5 N5 (15;) 0106#" #!./ ?>A;5@>4>2K5 N2 (156) 0103#" #!./ ?>A;5@>4>2K5 N4 (15;) 0103#" #!./ ?>A;5@>4>2K5 N5 (156) 0103#" #!./ ?>A;5@>4>2K5 N5 (15;) 0103"# ! , :0?A N30"# ! $ A0H5 2,03 N10"# ! ', :0?A N30!"# ! ' >G8I5=85 D/? 23 N20"#!! .! A8@>? 118? 100<3/5<; 118<;"+" :0?A N15"+ :0?A 450AA8O, 2@>?0-8>D0@<  "+ :0?A 450<3 N84%"+  4/2=CB@.?@85<0 D; 100"#% "# 0<? 2,2<; N5"#% "# 0<? 2,2D0@<#," :0?A 20@#,"  -! 0<? 2A=+C:@5?+?>:@ 15A=>20 15:@KB85 15AAB.?>2@.=>3B59 15;I.=>3B.15=48F8>=5@ 4/:CB8:C;K 15=48F8>=5@ 4/=>3B59 15@@.=5>4=>@.=>3B.15<; Fren(#/ -,  4/:CB8:C;K 153C@.3B.15<; Fren$#/ -, AC?5@-ACH:0 15:@KB85 15<; Fren(#/ -, C2;.35;L-C:@5?8B.153B59 153B.15<; Fren(#/ -, CA8;8B5;L F25B0 15<; Frenchi(#/ -, MDD5:B :@.=>3B59 154=>< 1074>@>2;5=8O :CB8:C;K 10<;'# ! 70I.4/A2.<0=.10<; +  '# ! 70I8B=.4/A256.<0=8:N@0 10=4.=>3B.10<;+ #" 4@065 N50 ;B09#" 4@065 N50 #$#! <  UPSA H8?.B01 500<3 N16$@0=F8O, UPSA Lab/Bristol&#!  UPSA H8?.B01 500;>:=O=:0) B01 N20 $$"#  $ 60% 20<; 0<? N10 A?0=8OA?0=8O, BerliMed"#  $ 76% 20<; 0<? N10 A?0=8O# ! D;-:0?. 25<;#  !" AC?? @5:B. 50<3 !10# !! :0?A 250<3 N10# !! :0?A 250<3 N50# !! :0?A 250?.3@0=C;K 103#! 3>?0B.B01 N20#!"- / .!#!!".+%.$" 25 20 40 20 20 20 20 40 40<3 N20 Hemofarm *&$ !"  B01 10<3 N10 Terapia C<K=8O, Terapia&$ !"  B01 10<3 N20 Terapia $ !" B01 10<3 N10 Terapia($ !" B01 10AA8O, Terapia/:@8E8= %$$!"# 35;L 2,5% 303$!"# 35;L 2,5% 503$ $ 35;L 2,5% 303$ $ 35;L 2,5% 503$  B01 50<3 N15$  B01 100<3 N15"$ :0?A 400<3+25 180 5<3 N30 IVAX$, B01 N20$ 4@065 N21$!" B01 2<3/10<3 N28$ B01 1<3 N50 )%$#" B01 250<3 N20 5;<54?@5?0@0BK$ 30@>2L5$!" 35;L 303$!" &  :@5< 1% 23*$!" &  :@5<$"  B01 100<3 N30 )$.,! :0?A 150<3 N10$.,! :0?A 150@.@-@0 0;8=0 A0H5 N8 Bris!$ ! ?0: N8 (1/A0E0@0) Bristol"$ ! ?0: N8 (A A0E0@><) Bristol'$  " ?0AB8;.652.503 $-#D08B0$  #  100<3 B01.652.N30$  #  100<3/2<; 2/< 0<? N5 $  #  100<3/2<; 2/< 0? D; 100 0,4<3 N14($!"  B.?>7.0406-01 N1$," #-!" B01 400<3 N50 $, 35;L 0,5% 353 5@<0=8O5@<0=8O, C.P.M.Contract Pharma$ <07L 203 5@<0=8O5@ 5<3 N30 $! "  B01 200<3 N50 * $! "  B01 400<3 N50 *$! B01 200<3 N50 *$"  #(+ N2 50AA8O, 50;LH0, Herbapol$"''+ B01 N10$"''+ B01 N50$"''+ B01 N10%$"!' #(+ 4/27@ N2 $8B>AA8O, $8B>=NE>2%$"!' #(+ 4/45B N2 $8B><548F8=0*$ !." B01 125<3 N20 Astellas 845@;0=4K, Astellas Pharma*$ !." B01 250<3 N20 Astellas *$ !." B01 500<3 N20 Astellas ($! !." B01 125<3 N20 Astellas($! !." B01 250<3 N20 Astellas($! !." B01 500<3 N20 Astellas$- B01 N100 Mucos$- B01 N200 Mucos$  $ " ?0: N30$# :0?A 150B5:A*$#!"- :0?A 20@0=040, Apotex/5:B>@($#!" :0?A 10@/Nu-Pharm0=040, 5:B>@/Nu-Pharm($#!" :0?A 10@/Nu-Pharm >AA8O, 5:B>@/Nu-Pharm$#&  35;L 153$#&  <07L 153$.!"" 0,2% 50<; D; N1%$.!"" 150<3 :0?A N1 $-5:A@54AB20$$.!"" 50<3 :0?A N7 $-5:A@54AB20$  B01 5<3 N28$#! :0?A N20$#! :0?A 0,4<3 N30 Zentiva$  B01 N28#$/ !" 1<3 N50 5;0@CAL *$/ !" 1<3 N50 ) *$  :0?A 50<3 N4 Cipla$  :0?A 150<3 N1 Cipla$  :0?A 150<3 N3 Cipla$   D; 50<; "25@L$   D; 50AA8O,  % $!$ D; ;8>D.4/8= 2,53 N5$  10000/1<; 0<? N105;L38O, Pfizer$  250@"$  500@$" B01 500AA8O, @18BA:89 %$$"  " <07L 153&$# & @-@ D; 10?0B:0$# & @-@ D; 10<; /$$$# & @-@ D; 25<; /$$$#  50<3 N30 "%$$#  B01 50@8A>2$# & @-@ 0,067% 10<; /$$#$# ! 0<? 1% 2@8A *"$# ! 0<? 1% 2<; N10 !5 *< $# ! B01 40<3 N50 Sopharma$# ! B01 40<A:$#"/  4/?CABKH:8 19578$#& " :@5< 153 @;0=48O% " @-@ 4/8=D 500<; N10%& :0?A 20<3 N28 %& :0?A 250<3 N6 Hemofarm%, B01 N50%& :0?A 500@#% @0AB2.G09 65;C4>G.A 4 <5A.2003(259F0@8O, Hipp/Domaco'% !...D; 0,05% 100<; 5B5@1&% ! "- A?@59 100AA8O, =8:A 4% $- (% $") <0A;.@-@ 2% 20 15 50<3 N30 Zentiva% B01 300? 100AA8O, ! /-:>D;>@%! 35;L 103% "-! :0?A 250<3 !50(% " !#,$" 0D.2/< 100<3N10% ! 35;L 5% 303 86D0@< % ! <07L 5% 303 86D0@<!% ! B01 250<3 !60 86D0@D5 4/?>E.68@>A6.1503 10%(%#  . :><?;.?8B0=.=0 54=.N5(&! ".! H8?.B01 500<3 N10 Zentiva(&! ".! H8?.B01 500<3 N20 Zentiva$&!" - A 30@0< :@5< 153&, " 0<? N5&, " 0<? N100&, " <07L 503&, " B01 N50'&' 4/?CABKH:8 A ?@8I.A 0 <5A 19502&  # "#  0<? N100&  # "#  0<? N5$& " 0<? 2/2, 2/< 250<3/<; 4<; !5& # 10<3 B01 N50#&"  ! :0?;8 10<3/<; 20? 5<3/5<; 75 10 10<3 N20&$ D; 13 2/2, 2/< 5;<54"&$ D; 13 2/2,2/  >AA8O, > "&$ D; 13 2/2,2/A8=B57 &$ D; 13 2/2,2/ $$%&$  @5:B.AC?? 50<3 N10 86D0@<%&$  @5:B.AC?? 100<3 N10 86D0@<%&$  @5:B.AC?? 250<3 N10 86D0@<&$  @5:B.AC?? N10 86D0@<!&$"! D; 13 2/2,2/< (&"!)=48O, Aurobindo Pharma Ltd&$"! D; 13 2/2,2/!&$" ! D; 13 2/2,2/< Alembic+&$" ! raymond weil online fargo k800i dolmar dect desktop macintosh : hi-fi 5003.17 () . zip lock 32 stihl 1 939 264-27-00 mobil gargoyle 939 xxx 2113 dr metabo li-da outlook -134 .- tognana mobihel electrolux 307 kiev apartaments service frigidaire kaasi 32 mobihel 2113 /